{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:52:40Z","timestamp":1792623160900,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.cyto.2012.02.006","type":"journal-article","created":{"date-parts":[[2012,3,6]],"date-time":"2012-03-06T09:53:54Z","timestamp":1331027634000},"page":"287-294","source":"Crossref","is-referenced-by-count":117,"title":["Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The diagnostic significance of interleukin-18 and interleukin-6"],"prefix":"10.1016","volume":"58","author":[{"given":"Masaki","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Nakagishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syuji","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Yachie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2012.02.006_b0005","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2012.02.006_b0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/095952879708000106","article-title":"On a form of chronic joint disease in children","volume":"80","author":"Still","year":"1897","journal-title":"Med Chir Trans"},{"key":"10.1016\/j.cyto.2012.02.006_b0015","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/01.bor.0000169363.69066.d0","article-title":"Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis","volume":"17","author":"Adams","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.cyto.2012.02.006_b0020","doi-asserted-by":"crossref","first-page":"R1281","DOI":"10.1186\/ar1826","volume":"7","author":"Woo","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cyto.2012.02.006_b0025","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/art.20944","article-title":"Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis","volume":"52","author":"Yokota","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2012.02.006_b0030","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2012.02.006_b0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/s10165-008-0116-2","article-title":"A case report of a patient with refractory adult-onset Still\u2019s disease who was successfully treated with tocilizumab over 6years","volume":"19","author":"Nakahara","year":"2009","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.cyto.2012.02.006_b0040","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10067-009-1097-z","article-title":"Glucocorticoid and cyclosporine refractory adult onset Still\u2019s disease successfully treated with tocilizumab","volume":"28","author":"Matsumoto","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cyto.2012.02.006_b0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ard.2008.088179","article-title":"TCZ for multirefractory AOSD","volume":"68","author":"De Bandt","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cyto.2012.02.006_b0050","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/s10165-010-0348-9","article-title":"Benefit and a possible risk of tocilizumab therapy for adult-onset Still\u2019s disease accompanied by macrophage-activation syndrome","volume":"21","author":"Kobayashi","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.cyto.2012.02.006_b0055","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/adc.85.5.421","article-title":"Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders","volume":"85","author":"Sawhney","year":"2001","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.cyto.2012.02.006_b0060","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/art.20198","article-title":"Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?","volume":"50","author":"Grom","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2012.02.006_b0065","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00002281-200209000-00012","article-title":"Macrophage activation syndrome","volume":"14","author":"Ravelli","year":"2002","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.cyto.2012.02.006_b0070","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/rheumatology\/40.11.1285","article-title":"Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients","volume":"40","author":"Stephan","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.cyto.2012.02.006_b0075","first-page":"121","article-title":"Is macrophage activation syndrome a new entity?","volume":"20","author":"Athreya","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.cyto.2012.02.006_b0080","first-page":"2513","article-title":"Macrophage activation syndrome \u2013 what\u2019s in a name!","volume":"30","author":"Ramanan","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.cyto.2012.02.006_b0085","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1128\/IAI.63.10.3966-3972.1995","article-title":"A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock","volume":"63","author":"Okamura","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.cyto.2012.02.006_b0090","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/378088a0","article-title":"Cloning of a new cytokine that induces IFN-\u03b3 production by T cells","volume":"378","author":"Okamura","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.cyto.2012.02.006_b0095","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1189\/jlb.0602313","article-title":"Interleukin-18","volume":"73","author":"Gracie","year":"2003","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.cyto.2012.02.006_b0100","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2249.2004.02475.x","article-title":"Interleukin-18 as a potential target in inflammatory arthritis","volume":"136","author":"Gracie","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.cyto.2012.02.006_b0105","doi-asserted-by":"crossref","first-page":"13962","DOI":"10.1073\/pnas.96.24.13962","article-title":"IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils","volume":"96","author":"Yoshimoto","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cyto.2012.02.006_b0110","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1002\/art.10389","article-title":"Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al.","volume":"46","author":"Maeno","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2012.02.006_b0115","first-page":"823","article-title":"Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis","volume":"34","author":"Lotito","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.cyto.2012.02.006_b0120","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1007\/s10067-006-0474-0","article-title":"Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis","volume":"26","author":"Jelusi\u0107","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cyto.2012.02.006_b0125","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","article-title":"Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis","volume":"49","author":"Shimizu","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.cyto.2012.02.006_b0130","first-page":"390","article-title":"International league of associations for rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.cyto.2012.02.006_b0135","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jpeds.2004.12.016","article-title":"Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"146","author":"Ravelli","year":"2005","journal-title":"J Pediatr"},{"key":"10.1016\/j.cyto.2012.02.006_b0140","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/art.1780391013","article-title":"Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile","volume":"39","author":"Grom","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2012.02.006_b0145","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cyto.2012.02.006_b0150","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.10885","article-title":"Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type","volume":"48","author":"Quartier","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2012.02.006_b0155","first-page":"401","article-title":"Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis","volume":"30","author":"Ramanan","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.cyto.2012.02.006_b0160","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.cyto.2012.02.006_b0165","first-page":"2071","article-title":"Effective use of the recombinant interleukin-1 receptor antagonist anakinra in therapy-resistant systemic onset juvenile rheumatoid arthritis","volume":"31","author":"Verbsky","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.cyto.2012.02.006_b0170","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","article-title":"Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients","volume":"50","author":"Miettunen","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.cyto.2012.02.006_b0175","first-page":"79","article-title":"Macrophage activation syndrome during anti-IL1 receptor therapy (anakinra) in a patient affected by systemic onset idiopathic juvenile arthritis","volume":"3","author":"Lurati","year":"2005","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.cyto.2012.02.006_b0180","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1189\/jlb.1105674","article-title":"Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer","volume":"80","author":"Rose-John","year":"2006","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.cyto.2012.02.006_b0185","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/art.1780340912","article-title":"Correlation of interleukin-6 levels with joint involvement and thrombocytosis in patients with systemic juvenile rheumatoid arthritis","volume":"34","author":"de Benedetti","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2012.02.006_b0190","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/art.20946","article-title":"Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis","volume":"52","author":"de Benedetti","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2012.02.006_b0195","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti\u2013IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2012.02.006_b0200","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1074-7613(00)80596-8","article-title":"Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function","volume":"9","author":"Adachi","year":"1988","journal-title":"Immunity"},{"key":"10.1016\/j.cyto.2012.02.006_b0205","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0952-7915(98)80163-5","article-title":"Regulation of interferon-gamma production by IL-12 and IL-18","volume":"10","author":"Okamura","year":"1998","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.cyto.2012.02.006_b0210","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar1453","article-title":"Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome","volume":"7","author":"Villanueva","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cyto.2012.02.006_b0215","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1067\/mpd.2003.110","article-title":"Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome","volume":"142","author":"Grom","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.cyto.2012.02.006_b0220","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1002\/art.24750","article-title":"Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis","volume":"60","author":"de Jager","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2012.02.006_b0225","first-page":"2290","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466612000580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466612000580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T19:36:19Z","timestamp":1593804979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466612000580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S1043466612000580"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2012.02.006","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}